An Overview of Racivir
May 29, 2013
Other Names: (+)/(-)-FTC, PSI-5004, RCV
What is an investigational drug?
An investigational drug is one that is under study and is not approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Medical research studies are conducted to evaluate the safety and effectiveness of an investigational drug. These research studies are also called clinical trials. Once an investigational drug has been proven safe and effective in clinical trials, FDA may approve the drug for sale in the United States.
What is racivir?
Racivir is an investigational drug that is being studied for the treatment of HIV infection.
Racivir belongs to a class (group) of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs).2 NRTIs block an HIV enzyme called reverse transcriptase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking reverse transcriptase, NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.
How are clinical trials of investigational drugs conducted?
Clinical trials are conducted in "phases." Each phase has a different purpose and helps researchers answer different questions.5
In most cases, an investigational drug must be proven safe and effective in a Phase III clinical trial to be considered for approval by the FDA for sale in the United States. Some drugs go through the FDA's accelerated approval process and are approved before a Phase III clinical trial is complete. After a drug is approved by the FDA and made available to the public, researchers track its safety in Phase IV trials to seek more information about the drug's risks, benefits, and optimal use.5
In what phase of testing is racivir?
Racivir has been studied in Phase II clinical trials.2
What have recent studies shown about racivir?
In a Phase II study, racivir was compared to lamivudine in HIV-infected participants who were already taking HIV medicines before entering the study (treatment-experienced) and who had the M184V HIV mutation (a mutation associated with drug resistance to the HIV medicine lamivudine). Before starting the study, all participants were on a failing antiretroviral therapy (ART) regimen that included lamivudine. (A failing ART regimen is one that is not effective at controlling a person's HIV.) Study participants were randomly assigned to receive either racivir in place of lamivudine or to continue with lamivudine as part of their ART.6,7
In this study, racivir was shown to decrease viral load (the amount of HIV in the blood) in the treatment-experienced adults who had the M184V resistance mutation and who had fewer than three thymidine analog mutations (HIV mutations associated with NRTI drug resistance). In terms of safety, no severe drug-related side effects occurred in either the racivir treatment group or the lamivudine treatment group.7
The Medicines Patent Pool (MPP) Broadens Collaboration With Gilead Sciences: Signs License for Phase III Medicine Tenofovir Alafenamide (TAF)
This article was provided by AIDSinfo. Visit the AIDSinfo website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)